Selentus Science is pleased to announce that its patent for TenaTac®, an innovative, adhesive surgical haemostat, has been allowed for grant in the UK, following an earlier grant in the USA. TenaTac is a Class III CE marked medical device that was approved for human surgical use in late 2019. TenaTac is now also available to veterinary surgeons in the UK; for further information please visit www.Selentus.com

This article was written by Medilink EM Member, Selentus Science.

For more information on Medilink Membership, click here

Latest Opportunities

AI Airlock pilot call for applications

Funding competition information Following the launch webinar on 23 July 2024, candidates can now apply…

Explore the Chinese Market with EFEC

Lily Lin, CEO of Excellence First Enterprise Consultancy (EFEC), will be visiting China from 13…

Pioneer Group launches Golden Ticket Programme for cardiometabolic health innovations

Pioneer Group, a specialist in life science infrastructure and venture building, has teamed up with…

Latest News

TBAT Innovation announces 2024 Innovation Challenge Top 10 Finalists

The Innovation Challenge 2024, proudly presented by TBAT Innovation, with Headline Sponsor Shakespeare Martineau, has…

Pioneer Group launches Golden Ticket Programme for cardiometabolic health innovations

Pioneer Group, a specialist in life science infrastructure and venture building, has teamed up with…

Health Tech Enterprise Innovation Voucher Competition is live

Applications are now open for the Health Tech Enterprise Innovation Voucher Competition, sponsored by product…